Innaxon Biosciences greatly values the relationship with our customers, and while this COVID-19 outbreak has been highly disruptive to everyone’s lives, our key priority is to support you and your important work.
As part of our business continuity plans, we have put measures and precautions in place to ensure the safety of our customers and employees, while continuing to serve the scientific community at the highest level possible. Innaxon Biosciences is closely monitoring the situation to take proactive steps that maintain our business and supply chain.
These changes include, but are not limited to:
- Following PHE and WHO guidelines on how to reduce risk to our employees and adopting proactive policies such as suspending all travel, restricting visitors, and providing flexible schedules to facilitate different working patterns.
- Strategically ordering materials in advance to secure critical materials to meet production requirements.
- Communicating with our supplier and world-wide distribution partners to minimize shipment disruption.
With these changes, Innaxon Biosciences is able to sustain business operations while safeguarding employees and customers. We are not currently experiencing any delays in distributing our products and our shipping department is operating at normal capacity.
We will continue to monitor the situation, follow guidelines from official health authorities, and take appropriate steps to protect the supply of our products.
We are proud to support multiple, innovative, pre-clinical projects on SARS-CoV-2 vaccine development by providing qualified adjuvants as sterile, aqueous solutions of high potency, long-life stability from large lot sizes.